“After numerous experiments and diligent analysis, this team presented the Batten community with a significant medical breakthrough – a treatment that slows the progression of juvenile Batten disease. At this very moment, it is undergoing FDA-required validation studies, with a goal of being approved into a clinical trial.
These studies are expected to last until late 2017 and projected to cost $3 million. Securing funding for this this project and successfully entering clinical trials, would mean that Will and the many children who need it most, would receive that treatment! And, HOPE researchers would gain valuable, much needed time to focus on finding a cure.“